Tandem Diabetes Care Announces Record Margins, New Tubeless Pump, and Pharmacy Shift

Company highlights strong Q4 performance, international expansion, and major reimbursement changes in the U.S.

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Tandem Diabetes Care (NASDAQ:TNDM) executives discussed the company's recent operating performance and strategic initiatives during a webcast event. Key highlights include record 58% gross margins in Q4, the upcoming launch of a new tubeless "Toby" pump feature, and a major shift to a "pay-as-you-go" model through the pharmacy channel in the U.S. market.

Why it matters

Tandem's strong financial performance, product pipeline, and reimbursement strategy shifts position the company to capitalize on the growing diabetes management market. The transition to pharmacy-based reimbursement could improve access and affordability for patients, while also boosting margins for Tandem over the long term.

The details

Tandem reported its highest-ever quarterly gross margin of 58% in Q4, driven by pricing, growing Mobi pump volumes, and the initial shift of t:slim supplies into the pharmacy channel. The company also outlined plans to launch a new tubeless "Toby" feature for its Mobi pump platform later this year. Internationally, Tandem is transitioning to a direct sales model in select markets, which it says provides higher average selling prices. In the U.S., Tandem is moving to a "pay-as-you-go" pharmacy-based reimbursement model, which it expects will provide a short-term revenue headwind of $70-$80 million in 2026 but higher long-term margins.

  • Tandem reported its Q4 2025 results in early 2026.
  • The company plans to launch its new tubeless "Toby" pump feature in the second half of 2026.
  • Tandem went live with direct sales in Switzerland, Austria, and the UK in Q1 2026.

The players

Tandem Diabetes Care

A medical device company focused on insulin delivery systems for people with insulin-dependent diabetes. Headquartered in San Diego, California, and founded in 2006.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

What’s next

The company said it expects the transition to pharmacy-based reimbursement to continue impacting its financials through 2026 and potentially into early 2027.

The takeaway

Tandem Diabetes is navigating a complex transition to a new reimbursement model and international expansion, but its strong product pipeline, financial performance, and focus on improving patient access position it well to capitalize on the growing diabetes management market.